Eyepoint Pharmaceuticals’ (EYPT) Sector Perform Rating Reiterated at Royal Bank Of Canada

Royal Bank Of Canada reissued their sector perform rating on shares of Eyepoint Pharmaceuticals (NASDAQ:EYPT) in a research note published on Tuesday, Marketbeat Ratings reports. They currently have a $5.00 price objective on the stock.

A number of other analysts have also recently issued reports on the company. Weiss Ratings reissued a “sell (d-)” rating on shares of Eyepoint Pharmaceuticals in a report on Friday, July 17th. JPMorgan Chase & Co. reaffirmed a “neutral” rating on shares of Eyepoint Pharmaceuticals in a report on Monday. HC Wainwright reiterated a “neutral” rating on shares of Eyepoint Pharmaceuticals in a research report on Tuesday. Chardan Capital reissued a “neutral” rating and issued a $5.00 price target (down from $65.00) on shares of Eyepoint Pharmaceuticals in a report on Monday. Finally, Guggenheim reissued a “buy” rating and issued a $68.00 price target on shares of Eyepoint Pharmaceuticals in a report on Wednesday, June 24th. One equities research analyst has rated the stock with a Strong Buy rating, four have assigned a Buy rating, five have given a Hold rating and one has issued a Sell rating to the stock. According to MarketBeat.com, the stock presently has a consensus rating of “Hold” and a consensus price target of $28.11.

Eyepoint Pharmaceuticals Price Performance

Shares of EYPT stock opened at $5.40 on Tuesday. The stock has a market capitalization of $465.53 million, a price-to-earnings ratio of -1.44 and a beta of 1.76. The company’s fifty day simple moving average is $12.71 and its two-hundred day simple moving average is $13.44. Eyepoint Pharmaceuticals has a 1 year low of $3.95 and a 1 year high of $19.11.

Eyepoint Pharmaceuticals (NASDAQ:EYPT) last posted its quarterly earnings results on Wednesday, August 5th. The company reported ($1.09) EPS for the quarter, missing analysts’ consensus estimates of ($1.01) by ($0.08). The company had revenue of $0.51 million during the quarter, compared to the consensus estimate of $0.45 million. Eyepoint Pharmaceuticals had a negative return on equity of 135.81% and a negative net margin of 10,994.73%. Equities research analysts anticipate that Eyepoint Pharmaceuticals will post -3.6 EPS for the current year.

Institutional Trading of Eyepoint Pharmaceuticals

Several institutional investors and hedge funds have recently modified their holdings of EYPT. KBC Group NV bought a new stake in shares of Eyepoint Pharmaceuticals during the 1st quarter valued at about $29,000. Mirae Asset Global Investments Co. Ltd. increased its position in shares of Eyepoint Pharmaceuticals by 51.0% in the fourth quarter. Mirae Asset Global Investments Co. Ltd. now owns 4,023 shares of the company’s stock worth $74,000 after purchasing an additional 1,358 shares during the last quarter. Russell Investments Group Ltd. bought a new position in shares of Eyepoint Pharmaceuticals in the third quarter worth approximately $76,000. Tower Research Capital LLC TRC raised its stake in Eyepoint Pharmaceuticals by 218.3% in the second quarter. Tower Research Capital LLC TRC now owns 8,700 shares of the company’s stock valued at $82,000 after purchasing an additional 5,967 shares in the last quarter. Finally, California State Teachers Retirement System raised its stake in Eyepoint Pharmaceuticals by 20.6% in the fourth quarter. California State Teachers Retirement System now owns 4,654 shares of the company’s stock valued at $85,000 after purchasing an additional 794 shares in the last quarter. Hedge funds and other institutional investors own 99.41% of the company’s stock.

Eyepoint Pharmaceuticals News Roundup

Here are the key news stories impacting Eyepoint Pharmaceuticals this week:

• Positive Sentiment: Management has argued that the failed LUGANO Phase 3 trial may have been distorted by an anomalous group of nine patients—about 4% of participants—with vision loss unrelated to wet AMD. The company also highlighted favorable secondary endpoints and Duravyu’s potential durability advantages. Positive results from the upcoming LUCIA Phase 3 trial, expected in the fourth quarter of 2026, could help restore confidence in the program. EyePoint: Sell-Off As Duravyu Fails Head-To-Head Study Vs Eylea May Be Overblown
• Neutral Sentiment: Unusually heavy options activity indicates elevated trading and hedging interest, but does not establish a clear directional signal for EYPT. Eyepoint Pharmaceuticals Sees Unusually Large Options Volume
• Negative Sentiment: EyePoint is facing a shareholder investigation by SueWallSt over potential securities-law claims. Such notices can add legal uncertainty and further weigh on investor sentiment. EYPT Shareholder Investigation
• Negative Sentiment: Analyst sentiment has deteriorated following the trial result. Chardan Capital lowered its rating to Neutral, while Royal Bank of Canada cut EyePoint to Sector Perform and set a $5 price target. HC Wainwright, Cantor Fitzgerald, and JPMorgan maintained neutral-equivalent ratings, and Jefferies reduced its expectations. The broad lack of bullish ratings limits near-term valuation support. Chardan Capital Rating
• Negative Sentiment: The LUGANO Phase 3 failure caused a sharp sell-off because Duravyu did not meet its primary endpoint against Eylea. Analysts continue to view the result as a substantial risk to EyePoint’s pipeline and valuation, despite management’s explanation and the pending LUCIA data. EyePoint: Still A Sell After Phase 3 Crash

About Eyepoint Pharmaceuticals

Eyepoint Pharmaceuticals, Inc is a biopharmaceutical company focused on the development and commercialization of therapies for the treatment of ocular diseases. The company’s proprietary platform centers on sustained-release formulations designed to improve drug delivery to the posterior segment of the eye, addressing conditions that often require repeated intravitreal injections or intensive topical regimens. Eyepoint’s commercial strategy combines in-house sales and marketing capabilities with targeted partnerships to bring its therapies to ophthalmologists and retina specialists across the United States.

Eyepoint’s lead products include YUTIQ, a fluocinolone acetonide intravitreal implant indicated for the prevention of relapse in non-infectious uveitis affecting the posterior segment of the eye, and DEXYCU, a dexamethasone intraocular suspension approved for postoperative inflammation following ocular surgery.